Chardan Capital Raises Better Therapeutics (NASDAQ:BTTX) Price Target to $17.00

Better Therapeutics (NASDAQ:BTTXGet Rating) had its price target lifted by Chardan Capital from $15.00 to $17.00 in a report issued on Friday, The Fly reports. They currently have a maintains rating on the stock.

Better Therapeutics Trading Up 11.6 %

Shares of BTTX stock opened at $2.22 on Friday. The company has a current ratio of 9.86, a quick ratio of 9.86 and a debt-to-equity ratio of 0.34. Better Therapeutics has a 1 year low of $0.91 and a 1 year high of $29.40. The stock has a fifty day moving average of $1.72 and a two-hundred day moving average of $2.30.

Better Therapeutics (NASDAQ:BTTXGet Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11). Equities analysts forecast that Better Therapeutics will post -1.99 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Geoffrey M. Parker acquired 25,000 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was acquired at an average price of $1.45 per share, for a total transaction of $36,250.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $58,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought a total of 32,281 shares of company stock worth $48,042 over the last 90 days. 59.40% of the stock is currently owned by company insiders.

Institutional Trading of Better Therapeutics

A hedge fund recently raised its stake in Better Therapeutics stock. Vanguard Group Inc. increased its position in Better Therapeutics, Inc. (NASDAQ:BTTXGet Rating) by 39.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 284,395 shares of the company’s stock after buying an additional 80,633 shares during the quarter. Vanguard Group Inc. owned about 1.20% of Better Therapeutics worth $563,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 14.97% of the company’s stock.

About Better Therapeutics

(Get Rating)

Better Therapeutics, Inc engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes.

Read More

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with's FREE daily email newsletter.